Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT1806 vs RoActemra in Methotrexate-Inadequate Rheumatoid Arthritis
2018-002202-31Phase 3Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omalizumab biosimilar SYN008 in rheumatoid arthritis (RA) (2 arms), sponsored by Bio-Thera Solutions, Ltd. Started Nov 2018; status: completed.
02
Drugs
omalizumab biosimilar SYN008
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2018-002202-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002202-31.